AU4139396A - Process for purifying and isolating 2'-deoxy-2',2'-diflu oronucleosides - Google Patents
Process for purifying and isolating 2'-deoxy-2',2'-diflu oronucleosidesInfo
- Publication number
- AU4139396A AU4139396A AU41393/96A AU4139396A AU4139396A AU 4139396 A AU4139396 A AU 4139396A AU 41393/96 A AU41393/96 A AU 41393/96A AU 4139396 A AU4139396 A AU 4139396A AU 4139396 A AU4139396 A AU 4139396A
- Authority
- AU
- Australia
- Prior art keywords
- mixture
- acid
- formula
- beta
- nucleoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Description
Title
PROCESS FOR PURIFYING AND ISOLATING
2 ' -DEOXY-2 ' , 2 " -DIFLUORONUCLEOSIDES
Technical Field
The invention pertains to the field of pharmaceutical chemistry and provides a process for purifying and isolating 2 ' -deoxy-2 ' ,2 ' -difluoronucleosides.
BacKground Art
The continued interest in the synthesis of 2'- deoxynucleosides and their analogues is reflected in their successful use as therapeutic agents in viral and cancerous diseases. A critical step in the overall synthesis of 2'- deoxynucleosides is purification and isolation of the desired beta-anomer form of the nucleoside. This is critical because processes for synthesizing of 2 ' - deoxynucleosides are typically non-stereoselective and form a mixture of alpha and beta nucleosides. • vorbruggen, et al., J. Orα. Chem.. _ _, 2084
(1976), M. Hofer, Chem. Ber. ___., 2777 (1960), Walker, et al., Nucleic Acid Research. 1 , 6827 (1984), R. P. Hodge et. al., J. Orσ. Chem.. 56. 1553 (1991), Tann, et. al. , _____ Orσ. Chem.. ___ , 3644 (1985), Howell, et. al. , J. Orσ. Chem.. 53, 85 (1988) and U.S. Patent 4,965,374, Chou, et al., all report various syntheses of a mixture of alpha and beta anomer deoxy nucleosides.
Despite the processing advances in nucleoside synthesis, there continues to be a need for a process capable of efficiently purifying and isolating beta-anomer
enriched 2 ' -deoxy-2 ' , 2 ' -difluoronucleosides in increased yields, wherein the difluoronucleosides have been synthesized in the absence of a catalyst.
Accordingly, the object of the present invention is to provide a process for efficiently purifying and isolating beta-anomer enriched 2 ' -deoxy-2 ' , 2 ' - difluoronucleosides .
Other objects and advantages of the present invention will become apparent from the following description of embodiments.
Disclosure of Invention
This invention is a process to purify and isolate a beta-anomer enriched nucleoside comprising:
providing a mixture containing R" and a beta-anomer enriched nucleoside of the formula
wherein each X is independently selected from hydroxy protecting groups and R' is a nucleobase of the formula
where W is an amino protecting group; and
R" is a nucleobase of the formula
where W' is an amino protecting group or hydrogen; in a high boiling solvent; b) diluting the mixture with an organic solvent selected from the group consisting of ethers, esters and nitriles; c) adding the diluted reaction mixture to aqueous acid; and d) holding the acid mixture so prepared at a temperature from 70°C to 100°C until the product of formula IB, where W is now W , has precipitated.
Best Mode For Carrying Out The Invention
Throughout this document, all temperatures are in degrees Celsius, all proportions, percentages and the like are in weights and units and all mixtures are in volume units, except where otherwise indicated. Anomeric mixtures are expressed as a weight/weight ratio or as a percent. The term "alkyl" alone or in combination refers to straight, cyclic and branched chain aliphatic hydrocarbon groups which preferably contain up to 7 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, n-hexyl, 3-methylpentyl groups and the like or substituted straight, cyclic and branched chain aliphatic hydrocarbons, such as chloroethyl, 1,2- dichloroethyl, and the like. The term "substituted" alone or in combination refers to a substitution by one or more
of the groups selected from cyano, halo, carboalkoxy, toluoyl, nitro, alkoxy, alkyl, and dialkylamino. The phrase "anomer-enriched" alone or in combination refers to an anomeric mixture wherein the ratio of a specified anomer is greater than 1:1 and includes substantially pure anomer.
Hydroxy protecting groups (X) refer to hydroxy protecting groups known in the art, as described in Chapter 3 of Protective Groups in Organic Chemistry. McOmie Ed., Plenum Press, New York (1973), and Chapter 2 of Protective Groups in Organic Synthesis. Green, John, J. Wiley and
Sons, New York (1981) . Preferred hydroxy protecting groups are ester forming groups such as formyl, acetyl, substituted acetyl, propionyl, butynyl, pivaloyl, 2- chloroacetyl, benzoyl, substituted benzoyl, phenoxycarbonyl, methoxyacetyl; carbonate derivatives such as phenoxycarbonyl, ethoxycarbonyl, t-butoxycarbonyl, vinyloxycarbonyl, 2,2, 2-trichloroethoxycarbonyl and benzyloxycarbonyl; alkyl ether forming groups such as benzyl, diphenylmethyl, triphenylmethyl, t-butyl, methoxymethyl, tetrahydropyranyl, allyl, tetrahydrothienyl, 2-methoxyethoxy methyl; carbamates such as N- phenylcarbamate and N-imidazoylcarbamate; more preferred are benzoyl, mono-substituted benzoyl and disubstituted benzoyl, acetyl, pivaloyl, triphenylmethyl ethers, and most preferred is benzoyl.
Amino protecting groups (W) are selected from the group consisting of silyl amine forming groups such as trialkylsilyl, including trimethylsilyl; isopropyldialkyl- silyl, alkyldiisopropylsilyl, triisopropylsilyl, 1,1,3,3- tetraisopropyldisloxanyl, t-butyldialkylsilyl and t- butyldiarylsilyl; carbamates such as t-butoxycarbonyl, benzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, and 4-nitrobenzyloxycarbonyl; formyl, acetyl, benzoyl and pivalamido; ether forming groups such as methoxymethyl, t-butyl, benzyl, allyl and tetrahydropyranyl; a preferred amino protecting group is trimethylsilyl.
The first step in the process of the claimed invention is to provide a mixture containing R" and a beta- anomer enriched nucleoside of the formula
wherein each X is independently selected from hydroxy protecting groups and R' is a nucleobase of the formula
where W is an amino protecting group; and R" is a nucleobase of the formula
where W' is an amino protecting group or hydrogen; in a high boiling solvent.
Such a mixture may be created in many different ways. Methods to synthesize such a mixture are described and claimed in European Patent Application No. 93304817.5. By following certain of the processes (not using a
catalyst; using an excess of R" nucleobase, pg. 9 EP 93304817.5; and using a high-boiling solvent, page 10, lines 13-17) described in European Patent Application No. 93304817.5, it is possible to prepare the beta-anomer enriched nucleosides in an alpha to beta anomeric ratio of from greater than 1:1 to less than or equal to 1:9. A large excess of R" must be used to obtain these ratios. The excess R" is separated from the desired product by the process of the current invention. The high boiling solvent is a solvent that has a boiling point above 70°C. The high boiling solvent is moderately polar, acid stable and non-nucleophilic. Typical high boiling solvents are aromatic haloalkyl, alkoxy and halo substituted aromatic solvents, and mixtures thereof. Preferred high boiling solvents are 1,2- dichloroethane, 1, 1,2-trichloroethane, glyme, diglyme, toluene, xylenes, anisole, dichlorobromomethane, chlorobenzene, dibromochloromethane, tribomomethane, dibromomethane, acetonitrile, propionitrile, dioxane and mixtures thereof, while more preferred is anisole.
Once a mixture containing R" and the described beta-anomer enriched nucleoside is provided, the process of the present invention proceeds as follows. First, the reaction mixture is diluted with an organic solvent with a boiling point greater than 60°C. Acceptable solvents are from the classes of ethers, esters, and nitriles; preferred examples are acetonitrile, ethyl acetate and tetrahydrofuran. The dilution is carried out at an elevated temperature, which may be the reaction temperature. The organic solvent should be heated to an elevated temperature, as well, and the temperature of both the reaction mixture and the solvent should be in the range from 70°C to 110°C. The most preferred solvent is acetonitrile. The amount of organic solvent added is in the range from 1 ml to 5 ml per 1 gram of R" (protected or
unprotected cytosine) used. No particular holding period is required after dilution of the reaction mixture; the diluted mixture may be taken immediately to the next step. The diluted reaction mixture is added to a large amount of aqueous acid at an elevated temperature. The purpose of the aqueous acid is to dissolve the excess R" (protected or unprotected cytosine) , which was used in the glycosylation reaction described on page 9 of EP application No. 93304817.5. Therefore, the amount and degree of acidity of the aqueous acid depends on the excess amount of R"
(protected or unprotected cytosine) used in the reaction itself. Further, the amount of aqueous acid also depends on the choice of acid substance used in preparing the aqueous acid. The most preferred acid is hydrochloric acid, used at a concentration from 1 N to 6 N, most preferably at 4 N. When that acid is used, and the amount of excess R" (protected or unprotected cytosine) is in the range from 5 X to 20 X, the amount of aqueous hydrochloric acid is from 3 ml to 5 ml per 1 gram of R" (protected or unprotected cytosine) used.
However, other aqueous mineral acids and conditions are also usable and may be preferred in various circumstances. For example, mineral acid substances such as sulfuric acid, sulfurous acid, phosphoric acid, nitric acid, and phosphonic acid may be used if desired by the operator. The concentration of the acid can be varied rather widely, approximately in inverse proportion to the acceptable volume of the total isolation step. In general, concentrations from 1 N to 10% can be used in the aqueous acid. The volume of aqueous acid must be optimized experimentally for the individual acid and the amount in the reaction mixture. The experiments needed are very simple, requiring the operator only to make successive adjustments of acid concentration and volume with the
specific reaction mixture in use, observing the solubility of the R" (protected or unprotected cytosine) in each case.
The aqueous acid need not be hot when it is combined with the reaction mixture. The aqueous acid may be at ambient temperature, so long as the complete mixture is warmed to a temperature in the range from 70°C to 100°C. The heat of reaction may be sufficient to bring the mixture to that temperature, or it may be necessary in some cases to heat the mixture externally. In some cases, the heat of reaction is greater than 100°C, so the reaction mixture must be cooled so that it stays below 100°C. This is so because it is important that the temperature of the aqueous acid not be so elevated that any of the protecting groups are prematurely cleaved at this step of the process. When acetonitrile is used as the organic solvent, the most highly preferred temperature is from 70°C to 80°C.
The acidic mixture resulting from addition of the diluted reaction mixture to the aqueous acid is held, preferably with moderate agitation, for a period of time. The physical changes which occur during this holding period are the dissolution of the excess R" (protected or unprotected cytosine) in the aqueous acidic layer, and the precipitation of the desired beta-nucleoside. The precipitation is selective, and the undesired alpha- nucleoside remains in large part dissolved in the organic layer. Thus, the acidic mixture must be held, at constant temperature, until those two physical changes have occurred. In general, a period of from 10 minutes to 1 hour is adequate. After a sufficient holding period, the precipitated beta-nucleoside is separated from the two liquid phases by filtration or centrifugation, and is washed with additional aqueous acid. The filtration or centrifugation should be carried out at approximately constant temperature to prevent dissolved R" (protected or unprotected cytosine) from precipitating out of solution.
Beta-nucleoside isolated and purified in this manner may still have an amino protecting group (W) present, or the amino protecting group (W) may have been cleaved, and replaced with a hydrogen atom. Beta-nucleoside isolated and purified in the above manner is of superior purity, with respect to alpha-nucleoside, R" (protected or unprotected cytosine) and other impurities, and it is also found that the desired product is prepared in superior yield. When the acidic mixture has been filtered or centrifuged to remove the solid product, the organic and aqueous layers of the filtrate are separated. The excess R" (protected or unprotected cytosine) is in the aqueous layer and may be removed from that layer and recycled back into the process. R" (protected or unprotected cytosine) may be recovered simply by cooling the aqueous layer and filtering the precipitated R" (protected or unprotected cytosine), or by making the aqueous layer basic, cooling the basic solution, and filtering to collect the precipitated R" (protected or unprotected cytosine) .
Recovered cytosine from the above process is routinely recycled into the process of making the mixture as described in EP No. 93304817.5. Thus, the claimed process provides for economical recycling of R" (protected or unprotected cytosine) , which is a beneficial property of the process.
The final phase of the process is the removal of the protecting groups X and any remaining W from the blocked purified, solid nucleoside of formula IB. The same anomeric ratio of unprotected nucleoside is obtained by removal of the protecting groups.
Most silyl-amino protecting groups are easily cleaved by use of a protic solvent, such as water or an alcohol. Most silyl-amino protecting groups are vulnerable to cleaving during contact with mineral acid. The acyl protecting groups, such as benzoyl and the acyl-amino
protecting groups, are removed by hydrolysis with a strong base at a temperature from 0°C to 100°C. Strong or moderately strong bases suitable for use in this reaction are bases which have a pKa (at 25°C) of 8.5 to 20.0. Such bases include alkali metal hydroxides such as sodium or potassium hydroxide; alkali metal alkoxides such as sodium methoxide or potassium £.-butoxide; alkali metal amides; amines such as diethylamine, hydroxylamine, ammonia and the like; and other common bases such as hydrazine and the like. At least one equivalent of base is needed for each protecting group.
The acyl protecting groups can also be removed with acid catalysts, such as methanesulfonic acid, hydrochloric acid, hydrobromic acid, sulfuric acid, or with acidic ion exchange resins. It is preferred to carry out such hydrolysis at relatively high temperature, such as the reflux temperature of the mixture, but temperatures as low as ambient may be used when particularly strong acids are used. Care must be taken to preserve these acyl protecting groups so that they are not prematurely cleaved during the early steps of the process of the invention.
The removal of ether protecting groups is carried out by known methods, for example, with ethanethiol and aluminum chloride. The i.-butyldimethylsilyl protecting group requires acid conditions, such as contact with gaseous hydrogen halide, for its removal.
Removal of the protecting groups may be conveniently carried out in alcoholic solvents, especially aqueous alkanols such as methanol. However, the deblocking reaction may also be carried out in any convenient solvent, such as polyols including ethylene glycol, ethers such as tetrahydrofuran, ketones such as acetone and methyl ethyl ketone, or dimethylsulfoxide. In a preferred embodiment, the deblocking reaction employs ammonia to remove a benzoyl hydroxy-
protecting group at a temperature of 10°C. It is preferable, however, to use an excess of base in this reaction, although the amount of excess base used is not crucial.
The resulting beta- enriched nucleoside
or an organic or inorganic acid addition salt thereof, may be extracted and/or isolated from the reaction mixture by the procedure described in U.S. Patent 4,965,374.
The following example illustrates specific aspects of the present invention and is not intended to limit the scope thereof in any respect and should not be so construed.
Example I
Preparation, purification and isolation of beta- anomer enriched 1- (2 ' -deoxy-2' ,2'-difluoro-3 ' , 5 '-di-O- benzoyl-D-ribofuranosyl)-4-aminopyrimidin-2-one with 22.5 equivalents of bis-trimethylsilylcytosine
To a 250 ml 3-neck flask were added 30 g of cytosine, 25 mg of ammonium sulfate and 150 ml of
hexamethyldisilazane, and the mixture was heated to 125°C and held for 30 minutes after the dissolution of all of the solids. Then the temperature was raised to 145°C, held until boiling stopped, and then held to 120°C under vacuum until solids began to form above the liquid level in the flask. Then the mixture was cooled to 105°C, and 25 ml of anisole was added.
In another 125 ml flask were combined 10 ml of anisole and 5.75 g of 2-deoxy-2, 2-difluoro-3 , 5-dibenzoyl-D- ribofuranosyl-1-α-methanesulfonate, and the mixture was heated until a homogeneous liquid was formed. That liquid was added at constant temperature to the cytosine mixture, and the combined mixture was held at 100°C for 24 hours. A 133 ml portion of 4N hydrochloric acid was placed in a 500 ml flask. A 31.3 ml portion of acetonitrile was added to the reaction mixture, and the diluted reaction mixture was then poured onto the acid with constant stirring, while a cooling bath was applied to the 500 ml flask. The combined mixture was then stirred at 70°C for 10 minutes, and was then filtered at constant temperature. The wet cake was then slurried for 10 minutes at 70°C with 25 ml of 4N hydrochloric acid, and was filtered again. That filter cake was slurried for 10 minutes at 70°C with 25 ml of deionized water, filtered, and the wet cake was slurried again at 70°C with 50 ml of deionized water. The pH of the aqueous slurry was raised to 7 with sodium bicarbonate, and the mixture was stirred for 10 minutes at 50°C or above, and was filtered again. That filter cake was slurried once more with 50 ml of deionized water at 70°C for 10 minutes, filtered, and the filter cake was dried and analyzed. It weighed 3.98 g, representing an isolated yield of 61 percent, and contained less than 1 percent of the undesired alpha-anomer.
The present invention has been described in detail, including the preferred embodiments thereof.
However, it will be appreciated that those skilled in the
art, upon consideration of the present disclosure, may make modifications and/or improvements on this invention that fall within the scope and spirit of the invention as set forth in the following claims.
Claims (8)
1. A process to purify and isolate a beta-anomer enriched nucleoside comprising:
a) providing a mixture containing R" and a beta-anomer enriched nucleoside of the formula
wherein each X is independently selected from hydroxy protecting groups and R' is a nucleobase of the formula
where W is an amino protecting group; and R" is a nucleobase of the formula
where W' is an amino protecting group or hydrogen; in a high boiling solvent; b) diluting the mixture with an organic solvent selected from the group consisting of ethers, esters and nitriles; c) adding the diluted reaction mixture to aqueous acid; and d) holding the acid mixture so prepared at a temperature from 70°C to 100°C until the product of formula IB, where W is now W', has precipitated.
2. A process of claim 1 wherein the reaction mixture is diluted with acetonitrile, ethyl acetate and tetrahydrofuran.
3. A process of Claim 2 wherein the reaction mixture is diluted with acetonitrile.
4. A process of claim 1 wherein the aqueous acid is hydrochloric acid from 1 N to 6 N. 5. A process of claim 1 wherein the acid mixture is agitated while the product is precipitating.
6. A process of claim 1 further including deblocking the purified formula IB product to form the nucleoside which is 1- (2 ' -deoxy-2 ' , 2 ' -difluoro-D- ribofuranosyl- -aminopyrimidin-2-one.
7. A process for purifying a beta-anomer enriched nucleoside substantially as hereinbefore described with reference to the example.
AMENDED CLAIMS
[received by the International Bureau on 08 April 1996 (08.04.1996); new claim 8 added; remaining claims unchanged (1 page)] b) diluting the mixture with an organic solvent selected from the group consisting of ethers, esters and nitriles; c) adding the diluted reaction mixture to aqueous acid; and d) holding the acid mixture so prepared at a temperature from 70°C to 100βC until the product of formula IB, where W is now ' , has precipitated.
2. A process of claim 1 wherein the reaction mixture is diluted with acetonitrile, ethyl acetate and tetrahydrofuran.
3. A process of Claim 2 wherein the reaction mixture is diluted with acetonitrile.
4. A process of claim 1 wherein the aqueous acid is hydrochloric acid from 1 N to 6 N.
5. A process of claim 1 wherein the acid mixture is agitated while the product is precipitating.
6. A process of claim 1 further including deblocking the purified formula IB product to form the nucleoside which is l-(2'-deoxy-2' ,2'-difluoro-D- ribofuranosyl-4-aminopyrimidin-2-one.
7. A process for purifying a beta-anomer enriched nucleoside substantially as hereinbefore described with reference to the example.
8. A process for purifying a beta-anomer enriched nucleoside substantially as hereinbefore described with reference to the examples, further comprising
(e) recovering R" for recycle.
STATEMENT UNDER ARTICLE 1 m
The International Search Report for the captioned application was mailed 08 February 1996. In accordance with Article 19 of the Patent Cooperation Treaty, applicant submits herewith a replacement sheet (page 15) for page 15 of the International Application as originally filed.
Claim 8 has been added and is directed to an alternative embodiments of the present invention. Support for this new claim is found on page 9, lines 10-26 of the specification.
In accordance with .-Article 19(2), the amendment does not go beyond the disclosure of the international application as filed. Applicant respectfully requests entry of the substitute sheet for page 15 of the International Application as originally filed.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/340,972 US5606048A (en) | 1992-06-22 | 1994-11-17 | Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
| US08/340972 | 1994-11-17 | ||
| PCT/US1995/014086 WO1996016072A1 (en) | 1994-11-17 | 1995-11-01 | Process for purifying and isolating 2'-deoxy-2',2'-difluoronucleosides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU4139396A true AU4139396A (en) | 1996-06-17 |
| AU702588B2 AU702588B2 (en) | 1999-02-25 |
Family
ID=23335711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU41393/96A Ceased AU702588B2 (en) | 1994-11-17 | 1995-11-01 | Process for purifying and isolating 2'-deoxy-2',2'-diflu oronucleosides |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US5606048A (en) |
| EP (1) | EP0712860B1 (en) |
| JP (1) | JPH10509170A (en) |
| KR (1) | KR100424990B1 (en) |
| CN (1) | CN1044119C (en) |
| AR (1) | AR001045A1 (en) |
| AT (1) | ATE210142T1 (en) |
| AU (1) | AU702588B2 (en) |
| BG (1) | BG62737B1 (en) |
| BR (1) | BR9509904A (en) |
| CA (1) | CA2205350C (en) |
| CO (1) | CO4600741A1 (en) |
| CZ (1) | CZ292013B6 (en) |
| DE (1) | DE69524365T2 (en) |
| DK (1) | DK0712860T3 (en) |
| ES (1) | ES2164745T3 (en) |
| HU (1) | HU219019B (en) |
| IL (1) | IL115854A (en) |
| MX (1) | MX9703548A (en) |
| MY (1) | MY115183A (en) |
| NO (1) | NO308305B1 (en) |
| NZ (1) | NZ296712A (en) |
| PE (1) | PE50196A1 (en) |
| PL (1) | PL182052B1 (en) |
| PT (1) | PT712860E (en) |
| RO (1) | RO118296B1 (en) |
| RU (1) | RU2161622C2 (en) |
| SI (1) | SI0712860T1 (en) |
| SK (1) | SK283160B6 (en) |
| TW (1) | TW377356B (en) |
| UA (1) | UA53614C2 (en) |
| WO (1) | WO1996016072A1 (en) |
| YU (1) | YU49446B (en) |
| ZA (1) | ZA959321B (en) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6326507B1 (en) * | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
| MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| CN101099745A (en) * | 2000-05-26 | 2008-01-09 | 艾登尼科斯（开曼）有限公司 | Methods and compositions for treating flaviviruses and pestiviruses |
| US7435755B2 (en) * | 2000-11-28 | 2008-10-14 | The Trustees Of Dartmouth College | CDDO-compounds and combination therapies thereof |
| AU2003235676A1 (en) * | 2002-01-15 | 2003-07-30 | Trustees Of Dartmouth College | Tricyclic-bis-enone derivatives and methods of use thereof |
| US7608600B2 (en) * | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
| RS113904A (en) * | 2002-06-28 | 2007-02-05 | Idenix (Cayman) Limited | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| CN101172993A (en) * | 2002-06-28 | 2008-05-07 | 埃迪尼克斯(开曼)有限公司 | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| US7265096B2 (en) * | 2002-11-04 | 2007-09-04 | Xenoport, Inc. | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof |
| HUE033832T2 (en) | 2002-11-15 | 2018-01-29 | Idenix Pharmaceuticals Llc | 2'-methyl nucleosides in combination with interferon and flaviviridae mutation |
| US7598373B2 (en) * | 2002-12-12 | 2009-10-06 | Idenix Pharmaceuticals, Inc. | Process for the production of 2-C-methyl-D-ribonolactone |
| EP1912643A2 (en) * | 2004-06-23 | 2008-04-23 | Idenix (Cayman) Limited | 5-aza-7-deazapurine derivatives for treating infections with flaviviridae |
| US7214791B2 (en) * | 2004-07-01 | 2007-05-08 | Shenzhen Hande Technology Co., Ltd. | Method for preparation of 2′-deoxy-2′, 2′-difluoro-β-cytidine or pharmaceutically acceptable salts thereof by using 1,6-anhydro-β-d-glucose as raw material |
| EP1819718A1 (en) * | 2004-12-08 | 2007-08-22 | Sicor Inc. | Difluoronucleosides and process for preparation thereof |
| BRPI0514718A (en) * | 2004-12-30 | 2008-07-01 | Hanmi Pharm Ind Co Ltd | Method for the preparation of 2'-deoxy-2 ', 2'-difluoro-cytidine |
| WO2006070985A1 (en) | 2004-12-30 | 2006-07-06 | Hanmi Pharm. Co., Ltd. | METHOD FOR THE PREPARATION OF 2#-DEOXY-2#,2#-DIFLUOROCYTIDINE |
| CA2598895A1 (en) * | 2005-03-04 | 2006-09-08 | Dabur Pharma Limited | Intermediate and process for preparing of beta- anomer enriched 21deoxy, 21 ,21-difluoro-d-ribofuranosyl nucleosides |
| JP4516863B2 (en) * | 2005-03-11 | 2010-08-04 | 株式会社ケンウッド | Speech synthesis apparatus, speech synthesis method and program |
| KR101171087B1 (en) * | 2005-06-03 | 2012-08-06 | 조오지 슐로에머 | Process of making an alpha-anomer enriched 2-deoxy-2,2-diflouro-d-ribofuranosyl sulfonate and use thereof for making a beta nucleoside |
| AU2011202539B2 (en) * | 2005-06-03 | 2012-07-05 | Scinopharm Taiwan, Ltd. | Process of making an alpha-anomer enriched 2-deoxy-2,2-difluoro-d-ribofuranosyl sulfonate and use thereof for making a beta nucleoside |
| EP1940859A1 (en) * | 2005-10-28 | 2008-07-09 | Arch Pharmalabs Limited | An improved process for preparation of gemcitabine hydrochloride |
| CA2634749C (en) * | 2005-12-23 | 2014-08-19 | Idenix Pharmaceuticals, Inc. | Process for preparing a synthetic intermediate for preparation of branched nucleosides |
| WO2007117760A2 (en) * | 2006-02-06 | 2007-10-18 | Dr. Reddy's Laboratories Ltd. | Preparation of gemcitabine |
| US8921340B2 (en) | 2006-11-17 | 2014-12-30 | Trustees Of Dartmouth College | Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions |
| WO2008064133A1 (en) * | 2006-11-17 | 2008-05-29 | Trustees Of Dartmouth College | Synthesis and biological activities of new tricyclic-bis-enones (tbes) |
| WO2008064132A2 (en) * | 2006-11-17 | 2008-05-29 | Trustees Of Dartmouth College | Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth |
| US7994310B2 (en) * | 2007-03-23 | 2011-08-09 | Dongwoo Syntech Co., Ltd. | Process for preparing 2′-deoxy-2′, 2′-difluorocytidine |
| CN100475832C (en) * | 2007-05-31 | 2009-04-08 | 南京卡文迪许生物工程技术有限公司 | Novel highly-solid selectively synthesizing gemcitabine process and intermediate |
| US20090048205A1 (en) * | 2007-08-15 | 2009-02-19 | Colin Meyer | Combination therapy with synthetic triterpenoids and gemcitabine |
| EP2050757A1 (en) | 2007-10-10 | 2009-04-22 | Cilag AG | Method of producing 2' -deoxy-5-azacytidine (Decitabine) |
| JO2778B1 (en) | 2007-10-16 | 2014-03-15 | ايساي انك | Certain Compounds, Compositions and Methods |
| CN101965184B (en) * | 2008-01-11 | 2015-03-11 | 里亚塔医药公司 | Synthetic triterpenoids and methods of use in the treatment of disease |
| EP2276493B1 (en) | 2008-04-18 | 2018-11-14 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17 |
| EP2279197B1 (en) * | 2008-04-18 | 2014-11-05 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring |
| MX339476B (en) * | 2008-04-18 | 2016-05-27 | Reata Pharmaceuticals Inc | Compounds including an anti-inflammatory pharmacore and methods of use. |
| TW201004627A (en) * | 2008-04-18 | 2010-02-01 | Reata Pharmaceuticals Inc | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
| WO2009129548A1 (en) | 2008-04-18 | 2009-10-22 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives |
| WO2010011782A1 (en) | 2008-07-22 | 2010-01-28 | Trustees Of Dartmouth College | Monocyclic cyanoenones and methods of use thereof |
| AU2010234562B2 (en) * | 2009-04-06 | 2016-05-12 | Otsuka Pharmaceutical Co., Ltd. | Combination of cytidine-based antineoplastic drugs with cytidine deaminase inhibitor and use thereof in the treatment of cancer |
| JO3262B1 (en) * | 2009-04-06 | 2018-09-16 | Otsuka Pharma Co Ltd | Combination of decitabine with cytidine deamiase inhibitor and use thereof in the treatment of cancer |
| JO3197B1 (en) * | 2009-04-06 | 2018-03-08 | Otsuka Pharma Co Ltd | (2'-deoxy-ribofuranosyl)-1,3,4,7-tetrahydro-(1,3)diazepin-2-one derivatives for treating cancer |
| US8609631B2 (en) | 2009-04-06 | 2013-12-17 | Eisai Inc. | Compositions and methods for treating cancer |
| PT2833905T (en) | 2012-04-04 | 2018-08-06 | Halozyme Inc | Combination therapy with hyaluronidase and a tumor-targeted taxane |
| US8921419B2 (en) | 2012-05-08 | 2014-12-30 | Trustees Of Dartmouth College | Triterpenoids and compositions containing the same |
| WO2019222435A1 (en) | 2018-05-16 | 2019-11-21 | Halozyme, Inc. | Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3282921A (en) * | 1964-06-04 | 1966-11-01 | Syntex Corp | Halo-deoxynucleosides and processes for the preparation thereof |
| US3721664A (en) * | 1970-01-27 | 1973-03-20 | Hoffmann La Roche | Preparation of 5-cytosine nucleosides |
| DE2628202A1 (en) * | 1976-06-23 | 1977-12-29 | Max Planck Gesellschaft | PROCESS FOR THE PREPARATION OF 2'-SUBSTITUTE-D-RIBOFURANOSYLPURINE DERIVATIVES |
| DE2721466A1 (en) * | 1977-05-12 | 1978-11-16 | Robugen Gmbh | PROCESS FOR THE PREPARATION OF 2'-DESOXYRIBOFURANOSYL NUCLEOSIDES |
| US4211773A (en) * | 1978-10-02 | 1980-07-08 | Sloan Kettering Institute For Cancer Research | 5-Substituted 1-(2'-Deoxy-2'-substituted-β-D-arabinofuranosyl)pyrimidine nucleosides |
| FI832884A (en) * | 1982-08-17 | 1984-02-18 | Sandoz Ag | DESOXYURIDINDERIVAT, DERAS FRAMSTAELLNINGSFOERFARANDEN OCH ANVAENDNING SOM PHARMACEUTISKA MEDEL |
| US4526988A (en) * | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
| US4625020A (en) * | 1983-11-18 | 1986-11-25 | Bristol-Myers Company | Nucleoside process |
| CA1295998C (en) * | 1985-07-29 | 1992-02-18 | Sai P. Sunkara | Nucleosides and their use as antineoplastic agents |
| US4751221A (en) * | 1985-10-18 | 1988-06-14 | Sloan-Kettering Institute For Cancer Research | 2-fluoro-arabinofuranosyl purine nucleosides |
| US5223608A (en) * | 1987-08-28 | 1993-06-29 | Eli Lilly And Company | Process for and intermediates of 2',2'-difluoronucleosides |
| US4965374A (en) * | 1987-08-28 | 1990-10-23 | Eli Lilly And Company | Process for and intermediates of 2',2'-difluoronucleosides |
| EP0339161A1 (en) * | 1988-04-01 | 1989-11-02 | Merrell Dow Pharmaceuticals Inc. | Novel fluorophosphonate nucleotide derivatives |
| JPH0232093A (en) * | 1988-06-08 | 1990-02-01 | Merrell Dow Pharmaceut Inc | Anti-retrovirus difluorinated nucleoside |
| HU906976D0 (en) * | 1989-11-13 | 1991-05-28 | Bristol Myers Squibb Co | Process for producing 2', 3'-didesoxy-2'-fluoarabinonucleoside analogues |
| US5175267A (en) * | 1990-03-02 | 1992-12-29 | University Of Georgia Research Foundation, Inc. | Stereoselective glycosylation of hetercyclic bases |
| US5401838A (en) * | 1992-06-22 | 1995-03-28 | Eli Lilly And Company | Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
| US5371210A (en) * | 1992-06-22 | 1994-12-06 | Eli Lilly And Company | Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
| UA41261C2 (en) * | 1992-06-22 | 2001-09-17 | Елі Ліллі Енд Компані | METHOD OF OBTAINING BETA-ANOMER-ENRICHED NUCLEOSIDES |
| US5426183A (en) * | 1992-06-22 | 1995-06-20 | Eli Lilly And Company | Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
-
1994
- 1994-11-17 US US08/340,972 patent/US5606048A/en not_active Expired - Lifetime
-
1995
- 1995-01-11 UA UA97052227A patent/UA53614C2/en unknown
- 1995-11-01 RO RO97-00898A patent/RO118296B1/en unknown
- 1995-11-01 JP JP8516877A patent/JPH10509170A/en not_active Ceased
- 1995-11-01 AU AU41393/96A patent/AU702588B2/en not_active Ceased
- 1995-11-01 KR KR1019970703223A patent/KR100424990B1/en not_active IP Right Cessation
- 1995-11-01 BR BR9509904A patent/BR9509904A/en not_active Application Discontinuation
- 1995-11-01 RU RU97110266/04A patent/RU2161622C2/en not_active IP Right Cessation
- 1995-11-01 WO PCT/US1995/014086 patent/WO1996016072A1/en active IP Right Grant
- 1995-11-01 MX MX9703548A patent/MX9703548A/en unknown
- 1995-11-01 CA CA002205350A patent/CA2205350C/en not_active Expired - Fee Related
- 1995-11-01 CZ CZ19971481A patent/CZ292013B6/en not_active IP Right Cessation
- 1995-11-01 NZ NZ296712A patent/NZ296712A/en not_active IP Right Cessation
- 1995-11-01 SK SK485-97A patent/SK283160B6/en not_active IP Right Cessation
- 1995-11-01 PL PL95320634A patent/PL182052B1/en unknown
- 1995-11-01 HU HU9800819A patent/HU219019B/en not_active IP Right Cessation
- 1995-11-01 CN CN95196272A patent/CN1044119C/en not_active Expired - Fee Related
- 1995-11-02 IL IL11585495A patent/IL115854A/en not_active IP Right Cessation
- 1995-11-03 MY MYPI95003339A patent/MY115183A/en unknown
- 1995-11-03 ZA ZA959321A patent/ZA959321B/en unknown
- 1995-11-09 SI SI9530573T patent/SI0712860T1/en unknown
- 1995-11-09 DK DK95308034T patent/DK0712860T3/en active
- 1995-11-09 AT AT95308034T patent/ATE210142T1/en active
- 1995-11-09 ES ES95308034T patent/ES2164745T3/en not_active Expired - Lifetime
- 1995-11-09 AR AR33417195A patent/AR001045A1/en unknown
- 1995-11-09 PT PT95308034T patent/PT712860E/en unknown
- 1995-11-09 DE DE69524365T patent/DE69524365T2/en not_active Expired - Lifetime
- 1995-11-09 EP EP95308034A patent/EP0712860B1/en not_active Expired - Lifetime
- 1995-11-10 PE PE1995284282A patent/PE50196A1/en not_active IP Right Cessation
- 1995-11-13 YU YU70995A patent/YU49446B/en unknown
- 1995-11-14 CO CO95053588A patent/CO4600741A1/en unknown
- 1995-11-14 TW TW084112040A patent/TW377356B/en not_active IP Right Cessation
-
1997
- 1997-05-14 BG BG101485A patent/BG62737B1/en unknown
- 1997-05-14 NO NO972214A patent/NO308305B1/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0712860B1 (en) | Process for purifying and isolating 2'-deoxy-2',2'-difluoronucleosides | |
| MXPA97003548A (en) | Process for purifying and isolating 2'-desoxy-2 ', 2'-difluoronucleosi | |
| US5426183A (en) | Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides | |
| EP0577304B1 (en) | Stereoselective anion glycosylation process | |
| EP0316017B1 (en) | 2',3'-Dideoxy-2'-fluoronucleosides | |
| JP2008531680A (en) | Intermediates and methods for the preparation of 21-deoxy-21,21-difluoro-D-ribofuranosyl nucleosides enriched in beta anomers | |
| EP0193903B1 (en) | Production of cytosine nucleosides | |
| WO2006070985A1 (en) | METHOD FOR THE PREPARATION OF 2#-DEOXY-2#,2#-DIFLUOROCYTIDINE | |
| EP0576232A1 (en) | Process for separating 2-deoxy-2, 2-difluoro-D-ribofuranosyl alkylsulfonate anomers | |
| EP1373288B1 (en) | Process for the preparation of 2'-halo-beta-l-arabinofuranosyl nucleosides | |
| AU2002303187A1 (en) | Process for the preparation of 2'-HALO-Beta-L-arabinofuranosyl nucleosides | |
| US8232387B2 (en) | Process for the preparation of cladribine | |
| AU659008B2 (en) | Stereoselective anion glycosylation process | |
| US20030162957A1 (en) | Protected deoxyadenosines and deoxyguanosines | |
| WO2002068437A1 (en) | Protected deoxyadenosines and deoxyguanosines |